Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
Fulgent Genetics, Inc. (FLGT)
|
Add to portfolio |
|
|
|
| Price: |
$87.75
| | Metrics |
| OS: |
29.9
|
M
| |
|
|
| Market cap: |
$2.63
|
B
| |
-5
|
% ROIC
|
|
Net cash:
|
$442
|
M
| |
$14.78
|
per share
|
|
EV:
|
$2.18
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($64.1)
|
M
| |
|
|
| EPS |
($0.32)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 992.6 | 421.7 | 32.5 | 21.4 | 18.7 | 18.3 | 9.6 | 1.3 |
| Revenue growth | 135.4% | 1196.5% | 52.3% | 14.0% | 2.5% | 90.9% | 649.3% | |
| Cost of goods sold | 215.5 | 89.8 | 14.1 | 10.7 | 8.6 | 6.7 | 5.1 | 0.9 |
| Gross profit | 777.1 | 331.9 | 18.4 | 10.7 | 10.2 | 11.6 | 4.5 | 0.3 |
| Gross margin | 78.3% | 78.7% | 56.6% | 49.9% | 54.3% | 63.2% | 47.1% | 26.8% |
| Sales and marketing | 24.4 | 15.0 | 5.9 | 4.7 | 4.2 | 2.5 | 2.7 | 0.6 |
| Research and development | 24.2 | 11.6 | 6.5 | 5.5 | 4.2 | 3.6 | 4.4 | 0.5 |
| General and administrative | 50.7 | 15.2 | 6.4 | 5.5 | 5.2 | 4.6 | 2.4 | 0.2 |
| EBITA | 677.7 | 289.7 | -1.2 | -6.0 | -4.0 | 0.9 | -5.0 | -1.0 |
| EBITA margin | 68.3% | 68.7% | -3.7% | -28.1% | -21.4% | 5.0% | -52.3% | -77.5% |
| Amortization of intangibles | 1.7 | | | | | | | |
| EBIT | 676.0 | 289.7 | -1.2 | -6.0 | -4.0 | 0.9 | -5.0 | -1.0 |
| EBIT margin | 68.1% | 68.7% | -3.7% | -28.1% | -21.4% | 5.0% | -52.3% | -77.5% |
| Pre-tax income | 677.3 | 291.7 | 0.4 | -4.6 | -3.0 | -4.5 | -5.0 | -1.0 |
| Income taxes | 174.8 | 72.5 | 0.0 | 0.0 | -1.0 | 0.9 | 0.0 | 0.0 |
| Tax rate | 25.8% | 24.9% | 10.5% | | 33.8% | | 0.0% | 0.0% |
| Earnings from continuing ops | 507.4 | 214.3 | -0.4 | -5.6 | -2.5 | -5.4 | -5.0 | -1.0 |
| Earnings from discontinued ops | | | | | | 0.0 | -3.3 | -3.3 |
| Net income | 507.4 | 214.3 | -0.4 | -5.6 | -2.5 | -5.3 | -8.3 | -4.3 |
| Net margin | 51.1% | 50.8% | -1.3% | -26.3% | -13.4% | -29.3% | -86.8% | -335.1% |
| |
| Diluted EPS | $16.38 | $8.91 | ($0.02) | ($0.31) | ($0.14) | ($0.39) | ($0.42) | |
| Shares outstanding (diluted) | 31.0 | 24.1 | 18.7 | 18.0 | 17.7 | 13.7 | 11.8 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|